22,247 Shares in Roivant Sciences Ltd. $ROIV Acquired by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 22,247 shares of the company’s stock, valued at approximately $483,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Rubric Capital Management LP increased its holdings in Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares during the period. State Street Corp boosted its position in Roivant Sciences by 4.8% in the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after purchasing an additional 911,827 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Roivant Sciences by 18.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company’s stock worth $140,839,000 after purchasing an additional 1,423,074 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Roivant Sciences by 11,507.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after purchasing an additional 6,877,348 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Roivant Sciences by 316.5% in the 3rd quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock worth $60,187,000 after purchasing an additional 3,022,851 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Activity

In other news, insider Frank Torti sold 1,400,000 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the transaction, the insider owned 13,736,547 shares in the company, valued at $376,656,118.74. This trade represents a 9.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the transaction, the chief executive officer owned 1,654,597 shares in the company, valued at $43,830,274.53. This trade represents a 10.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 5,085,398 shares of company stock worth $139,215,946. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on ROIV. Citigroup upped their price objective on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. HC Wainwright upped their price objective on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Guggenheim upped their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.55.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $27.83 on Monday. Roivant Sciences Ltd. has a 1 year low of $10.58 and a 1 year high of $30.33. The firm has a market capitalization of $19.92 billion, a price-to-earnings ratio of -23.79 and a beta of 1.14. The business’s 50 day moving average price is $28.30 and its 200-day moving average price is $24.01.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.